MedMira's HIV Test Approved Under USAID Initiative - Allows for International Purchase as Part of US Presidential Plan for AIDS Relief

    HALIFAX, Nov. 15 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ:   MMIRF), a global market leader in premium rapid diagnostic solutions,
announced today that its Reveal G3 Rapid HIV-1 Antibody Test ("Reveal G3") has
been approved for purchase by the U.S. Agency for International Development
("USAID"), resulting in the placement of Reveal G3 on USAID's rapid HIV test
procurement list. USAID's office of HIV/AIDS is responsible for leading the
Agency's efforts within the President's Emergency Plan for AIDS Relief
("PEPFAR"); a $15 billion multifaceted approach to combating HIV and AIDS in
over 100 countries, with particular emphasis on fifteen focus countries in
Africa, Asia and Latin America. MedMira's inclusion on this procurement list
enables Reveal G3 to be purchased for USAID-funded projects, and permits
countries receiving USAID funding to purchase Reveal G3 under the PEPFAR
    In order to be included on the USAID Procurement List, a rapid HIV test
must meet certain performance specifications which, in turn, offers both the
agency and the purchaser assurances that the product to be purchased is of the
highest quality, safety and efficacy. Reveal G3 is the most advanced test in
MedMira's Reveal product line, and was approved by the US Food and Drug
Administration (FDA) only last year. Reveal G3 is one of only five products on
the USAID list having FDA approval, thus offering purchasers of the test yet
another level of confidence in product performance and quality.
    "Since the FDA's approval of the original Reveal test, over 4 years ago,
MedMira has established itself in the U.S. market as having a high quality
product, which, by this inclusion on the USAID list, will now be available to
the countries worldwide where it is most needed," said Hermes Chan, President
and Chief Executive Officer of MedMira. "We pride ourselves on the excellent
performance of our rapid testing platform, and are extremely pleased to play a
part of the deliverance of quality testing to these countries for the fight
against HIV/AIDS."

    About USAID

    USAID ( plays a vital role in promoting U.S.
national security, foreign policy, and the War on Terrorism. It does so by
addressing poverty fueled by lack of economic opportunity, one of the root
causes of violence today. As stated in the President's National Security
Strategy, USAID's work in development joins diplomacy and defense as one of
three key pieces of the nation's foreign policy apparatus. USAID promotes
peace and stability by fostering economic growth, protecting human health,
providing emergency humanitarian assistance, and enhancing democracy in
developing countries. These efforts to improve the lives of millions of people
worldwide represent U.S. values and advance U.S. interests for peace and

    About MedMira

    MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals around the world with reliable, rapid diagnosis for diseases such
as HIV and hepatitis C in just three minutes. The company's tests are sold
under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in
global markets. MedMira's rapid HIV test is the only one in the world to
achieve regulatory approvals in Canada, the United States, China and the
European Union.
    In January 2006, MedMira launched the Maple Biosciences division to
develop and commercialize diagnostic instruments based on two revolutionary
biosensor-based technology platforms. The solutions developed by Maple
Biosciences will enable routine laboratory tests to be performed in a matter
of minutes, increasing laboratory automation, streamlining the diagnosis of
multiple conditions and diseases and positioning MedMira to be a leading
participant in the emerging fields of personalized medicine and molecular
diagnostics. For more information visit
    MedMira's corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada with a representative office in China. Maples
Biosciences' labs are located in Toronto, Ontario. For more information visit
MedMira's website at

    This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this statement.
    %SEDAR: 00013053E

For further information:

For further information: Dr. James Smith, Investor Relations & Corporate
Affairs, (902) 450-1588,

Organization Profile

MedMira Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890